Thermo Fisher Scientific (NYSE:TMO) had its target price raised by research analysts at Morgan Stanley from $223.00 to $227.00 in a report released on Thursday. The firm currently has an “overweight” rating on the medical research company’s stock. Morgan Stanley’s target price suggests a potential upside of 2.09% from the company’s current price.
Other equities analysts have also recently issued research reports about the company. Barclays raised their price objective on Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a report on Thursday. Leerink Swann restated an “outperform” rating and issued a $239.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Thursday. They noted that the move was a valuation call. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price objective for the company in a report on Tuesday, October 31st. BTIG Research assumed coverage on Thermo Fisher Scientific in a report on Friday, January 5th. They issued a “buy” rating and a $230.00 price objective for the company. Finally, Evercore ISI assumed coverage on Thermo Fisher Scientific in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 price objective for the company. Two research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $220.50.
Shares of Thermo Fisher Scientific (TMO) traded down $1.75 during midday trading on Thursday, hitting $222.36. The stock had a trading volume of 1,897,309 shares, compared to its average volume of 1,606,986. The company has a market cap of $89,400.00, a PE ratio of 39.71, a price-to-earnings-growth ratio of 1.74 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. Thermo Fisher Scientific has a 12 month low of $150.23 and a 12 month high of $226.44.
In related news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the sale, the chief executive officer now directly owns 252,577 shares in the company, valued at approximately $47,582,981.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.49% of the company’s stock.
A number of large investors have recently modified their holdings of TMO. Bank of Nova Scotia Trust Co. acquired a new stake in Thermo Fisher Scientific during the third quarter worth approximately $106,000. Ropes Wealth Advisors LLC lifted its position in Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after acquiring an additional 97 shares during the last quarter. Atlantic Trust LLC acquired a new stake in Thermo Fisher Scientific during the second quarter worth approximately $138,000. Acrospire Investment Management LLC lifted its position in Thermo Fisher Scientific by 66.7% during the second quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock worth $174,000 after acquiring an additional 400 shares during the last quarter. Finally, Glassman Wealth Services lifted its position in Thermo Fisher Scientific by 23.1% during the second quarter. Glassman Wealth Services now owns 1,039 shares of the medical research company’s stock worth $181,000 after acquiring an additional 195 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.